Clinical equivalence of intranasal and oral 17β-estradiol for postmenopausal symptoms

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 3, 2000, Pages 545-552

  Mattsson, Lars Ake ^a   Christiansen, Claus ^a   Colau, Jean Claude ^a   Palacios, Santiago ^a   Kenemans, Peter ^a   Bergeron, Christine ^a   Chevallier, Olivier ^a   Von Holst, Thomas ^a   Gangar, Kevin ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Estradiol; Estrogen replacement therapy; Intranasal therapy; Kupperman index; Postmenopausal symptoms; Randomized controlled double blind study

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; ESTROGEN THERAPY; FEMALE; FIRST PASS EFFECT; HUMAN; MAJOR CLINICAL STUDY; MASTALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UTERUS BLEEDING;

EID: 0034127504     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.104843     Document Type: Article

References (23)

1. 1. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994;330:1062-71.
2. 2. Kupperman HS, Blatt MH, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13: 688-703.
3. 3. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N EngI J Med 1996; 335:453-61.
4. 4. Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen: evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976;1:1038-41.
5. 5. O'Connell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 1995; 35(Suppl 9):18S-24S.
6. 6. De Lignieres B, Basdevant A, Thomas G, Thalabard JC, Mercier-Bodard C, Conard J, et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41.
7. 7. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and cholecystectomy in a large prospective study. Obstet Gynecol 1994;83:5-11.
8. 8. Daly E, Vessey M, Hawkins M, Carson J, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-80.
9. 9. Stanczyk FZ, Shoupe D, Nunez V, Macias-Gonzales P, Vijod MA, Lobo RA. A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988; 159:1540-6.
10. 10. Anonymous. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group. Int J Fertil Menopausal Stud 1993;38:5-11.
11. 11. Frenkel Y, Kopernik G, Lazer S, Tugendreich D, Zmira N, Oettinger M, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
12. 12. Studd JW, Pornel B, Marton I, et al. Dose-response study of the efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms. Lancet 1999;353:1574-8.
13. 13. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am J Obstet Gynecol 1993;168:824-30.
14. 14. Kurman RJ, Norris HJ. Endometrial hyperplasia and Related Cellular Changes. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. New York: Springer Verlag; 1994. p. 411-37.
15. 15. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-9.
16. 16. Reginster JY, Albert A, Deroisy R, Colette J, Vrijens B, Blacker C, et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50 [published erratum appears in Maturitas 1997; 28:193-5]. Maturitas 1997;27:179-86.
17. 17. Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in post-menopausal women taking sequential, combined estradiol and dydrogesterone. Maturitas 1997;26: 219-26.
18. 18. Wren BG, Brown L. Compliance with hormonal replacement therapy. Maturitas 1991;13:17-21.
19. 19. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial cholesterol levels. N Engl J Med 1996;335:1001-9.
20. 20. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998;31:1252-7.
21. 21. Voetberg GA, Netelenbos JC, Kenemans P, Peters-Mullet ER, van de Weijer PH. Estrogen replacement therapy coutinuously combined with four different dosages of dydrogesterone: effect on calcium and lipid metabolism. J Clin Endocrinol Metab 1994;79:1465-9.
22. 22. Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. Effects of oral and transdermal hormone replacement therapy on lipoprotein(A) and lipids: a randomized controlled trial. Menopause 1998;5:157-62.
23. 23. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26.